Clinical trials
Colonic Neoplasms trials in Turkey (Türkiye)
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 9 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Acibadem University | 2 |
| Istanbul Medipol University Hospital | 2 |
| Izmir Bakircay University | 2 |
| Atılım University | 1 |
| Bagcilar Training and Research Hospital | 1 |
| Bahçeşehir University | 1 |
| Bakirkoy Dr. Sadi Konuk Research and Training Hospital | 1 |
| Bilecik Seyh Edebali Universitesi | 1 |
| Cardiovascular and Interventional Radiological Society of Europe | 1 |
| Cukurova University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colonic Neoplasms | 29 |
| Colorectal Neoplasms | 6 |
| Breast Neoplasms | 4 |
| Rectal Neoplasms | 4 |
| Neoplasms | 3 |
| Anastomotic Leak | 2 |
| Anxiety Disorders | 2 |
| Colonic Diseases | 1 |
| Colonic Polyps | 1 |
| Diverticular Diseases | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.